Zimmer Biomet Holdings, Inc.’s stock price plunges to $90.48, marking a steep 11.62% decline

Zimmer Biomet Holdings, Inc. (ZBH)

90.48 USD -11.90 (-11.62%) Volume: 7.06M

Zimmer Biomet Holdings, Inc.’s stock price is currently at 90.48 USD, experiencing a significant drop of 11.62% this trading session with a trading volume of 7.06M. The medical device company’s stock has also seen a year-to-date decline of 14.34%, underlining a challenging period for ZBH investors.

Latest developments on Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings Inc. has been facing challenges with its 2025 profit forecast due to acquisition costs and tariff uncertainty, leading to a decrease in stock price. Despite announcing strong first-quarter financial results, the company had to scale back its profit forecast, causing shares to fall. Analysts have also adjusted their price targets for Zimmer Biomet stock, with Citigroup cutting it to $104 and RBC Capital reducing it as well. The company’s stock performance on Monday underperformed compared to competitors, with U.S. indexes also seeing a decrease. Zimmer Biomet’s focus on navigating growth amid tariff and integration challenges has been tested, but the company remains optimistic about future innovation and growth opportunities.

Zimmer Biomet Holdings, Inc. on Smartkarma

Special Situation Investments recently published a bullish research report on Zimmer Biomet Holdings, focusing on the acquisition of Paragon 28. The report evaluates the free CVR opportunity and growth potential of the acquisition. Zimmer Biomet is set to acquire Paragon 28 for $13/share in cash along with a non-transferable CVR linked to 2026 revenue. The CVR offers a potential payout of up to $1/share if Paragon’s revenue hits $361m, requiring a 19% CAGR over two years. With management support and minimal regulatory hurdles, the merger is expected to proceed smoothly, with DaCosta driven to meet the CVR targets.

A look at Zimmer Biomet Holdings, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, Zimmer Biomet Holdings has a positive long-term outlook. With high scores in value, growth, and momentum, the company is positioned well for future success. The company’s focus on designing and developing medical equipment, including orthopedic and dental implants, demonstrates its commitment to innovation and meeting the needs of patients globally.

While Zimmer Biomet Holdings also scores well in resilience, indicating its ability to weather economic challenges, the slightly lower score in dividends suggests potential room for improvement in this area. Overall, investors may find Zimmer Biomet Holdings to be a promising investment opportunity with strong potential for growth and value appreciation in the long run.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma